ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 028,90
0,00%
Dow Jones
44 593,65
0,28%
DAX
22 037,83
0,48%
Brent Oil
76,455
-0,23%
Bitcoin
96 148,81
0,42%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Glaukos Corporation (GKOS)

  7. Glaukos Corporation (GKOS) Actualités

GKOS

Glaukos (GKOS)

Glaukos Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:GKOS
DateHeureSourceTitreSymboleSociété
25/01/202500h33Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNYSE:GKOSGlaukos Corporation
23/01/202513h00Business WireGlaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20NYSE:GKOSGlaukos Corporation
14/01/202522h05Edgar (US Regulatory)Form 8-K - Current reportNYSE:GKOSGlaukos Corporation
14/01/202522h05Business WireGlaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical PlatformNYSE:GKOSGlaukos Corporation
03/01/202502h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:GKOSGlaukos Corporation
23/12/202413h00Business WireGlaukos Submits New Drug Application to U.S. FDA for Epioxa™NYSE:GKOSGlaukos Corporation
20/12/202422h27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:GKOSGlaukos Corporation
17/12/202413h00Business WireGlaukos Announces Participation in the J.P. Morgan Healthcare ConferenceNYSE:GKOSGlaukos Corporation
08/11/202413h00Business WireGlaukos Announces Participation in Upcoming Investor ConferencesNYSE:GKOSGlaukos Corporation
04/11/202422h05Business WireGlaukos Announces Third Quarter 2024 Financial ResultsNYSE:GKOSGlaukos Corporation
16/10/202422h05Business WireGlaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and SafetyNYSE:GKOSGlaukos Corporation
14/10/202413h00Business WireGlaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual MeetingNYSE:GKOSGlaukos Corporation
09/10/202413h00Business WireGlaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4NYSE:GKOSGlaukos Corporation
02/08/202422h51Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NYSE:GKOSGlaukos Corporation
02/08/202422h44Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:GKOSGlaukos Corporation
31/07/202422h05Business WireGlaukos Announces Second Quarter 2024 Financial ResultsNYSE:GKOSGlaukos Corporation
10/07/202413h00Business WireGlaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31NYSE:GKOSGlaukos Corporation
14/06/202413h00Business WireGlaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common StockNYSE:GKOSGlaukos Corporation
30/05/202422h45Edgar (US Regulatory)Form SD - Specialized disclosure reportNYSE:GKOSGlaukos Corporation
01/05/202422h05Business WireGlaukos Announces First Quarter 2024 Financial ResultsNYSE:GKOSGlaukos Corporation
16/04/202422h05Business WireGlaukos Announces the Release of its 2023 Sustainability ReportNYSE:GKOSGlaukos Corporation
10/04/202413h00Business WireGlaukos to Release First Quarter 2024 Financial Results after Market Close on May 1NYSE:GKOSGlaukos Corporation
03/04/202413h00Business WireGlaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)NYSE:GKOSGlaukos Corporation
01/04/202413h00Business WireGlaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual MeetingNYSE:GKOSGlaukos Corporation
05/03/202402h07Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NYSE:GKOSGlaukos Corporation
23/02/202423h23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NYSE:GKOSGlaukos Corporation
21/02/202422h05Business WireGlaukos Announces Fourth Quarter and Full Year 2023 Financial ResultsNYSE:GKOSGlaukos Corporation
13/02/202423h41Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NYSE:GKOSGlaukos Corporation
31/01/202413h00Business WireGlaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21NYSE:GKOSGlaukos Corporation
09/01/202413h00Business WireGlaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue GuidanceNYSE:GKOSGlaukos Corporation
 Showing the most relevant articles for your search:NYSE:GKOS

Dernières Valeurs Consultées

EU
BNP
BNP Paribas
EU
AF
Air FranceKLM
COIN
DOGEUSD
Dogecoin
EU
RNO
Renault
FTSE
UKX
FTSE 100
NYSE
DIS
Walt Disney
USI
USTECH100
US Tech 100
NYSE
MCD
McDonalds
EU
CAP
Capgemini
EU
SGO
Cie de SaintGobain
EU
EN
Bouygues
EU
PX1
CAC 40
EU
HO
Thales
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces